USNA
NYEUSANA Health Sciences Inc.
Consumer Defensive•Household & Personal Products
Watchlists:
Last updated: Friday 18th July 2025
30.63
-0.70 (-2.23%)
Prev Close:31.33
Open:31.26
Bid:30.0
Ask:49.21
52 Week Range
23.1046.95
Volume:169,064
Mkt Cap:583 M
54
MarketXLS Rank ®
Hold
Price Target
$35.22
+15.0%
Valuation
17.91
Range data not available
Returns
-8.32%
0.59%
28.54%
-35.11%
-53.72%
-66.41%
-14.66%
Risk
Risk Metrics
Financial Scores
0.00
3.27
Ranks
Financial Scores
Risk Metrics
Dividends
Dividend Metrics
Dividend Yields
Analyst Estimates
EPS Estimates
Target Prices
Growth Estimates
Financial Health
Cash Metrics
Liquidity Ratios
2.10
1.30
Debt Metrics
Other Metrics
Financial Scores
2.0
Technicals
Technical Oscillators
Moving Averages
Volatility Metrics
Growth
EPS
QoQ
N/A
YoY
N/A
Revenue
QoQ
N/A
YoY
N/A
Free Cash Flow
QoQ
N/A
YoY
N/A
Profitability
Return Ratios
Margin Ratios
Financial Scores
Peers
Financial Statements
USNA - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation And Amortization | 15 M | 13 M | 11 M | 12 M | 12 M | 13 M | -15 M | -14 M | -12 M | -9 M |
| Gain On Sale Of Security | 276000.0 | |||||||||
| General And Administrative Expense | 263 M | 257 M | 262 M | 279 M | 261 M | 268 M | -11 M | -11 M | -10 M | -11 M |
| Gross Profit Margin (profit Margin After CGS) | 693 M | 744 M | 805 M | 969 M | 926 M | 873 M | 989 M | 868 M | 826 M | 759 M |
| Impairment Of Capital Assets | -3 M | |||||||||
| Interest Expense Non Operating | 281000.0 | 262000.0 | 192000.0 | 57000.0 | 507000.0 | 66000.0 | 36000.0 | 46000.0 | 444000.0 | 15000.0 |
| Minority Interests | -30000.0 | |||||||||
| Misc Other Special Charges | -1 M | 7000.0 | -3 M | -2 M | -571000.0 | -335000.0 | -1 M | -3000.0 | -1 M | -174000.0 |
| Net Income (loss) | 42 M | 64 M | 69 M | 117 M | 125 M | 101 M | 126 M | 63 M | 100 M | 95 M |
| Net Income Common Stockholders | 42 M | 64 M | 69 M | 117 M | 125 M | 1,019 M | 126 M | 63 M | 100 M | 95 M |
| Net Income Continuous Operations | 42 M | 64 M | 69 M | 117 M | 125 M | 101 M | 126 M | 63 M | 100 M | 95 M |
| Net Non Operating Interest Income Expense | 11 M | 9 M | 4 M | 2 M | 2 M | 5 M | 4 M | 2 M | 1 M | 1 M |
| Operating Income | 66 M | 93 M | 108 M | 170 M | 176 M | 146 M | 188 M | 133 M | 139 M | 142 M |
| Operating Income Before Depreciation (EBITDA) | 99 M | 123 M | 130 M | 193 M | 201 M | 174 M | 208 M | 151 M | 152 M | 153 M |
| Operating Expense | 627 M | 651 M | 697 M | 798 M | 749 M | 727 M | 800 M | -735 M | -687 M | 617 M |
| Other Gand A | 263 M | 257 M | 262 M | 279 M | 261 M | 268 M | -11 M | -11 M | -10 M | -11 M |
| Other Operating Expenses | -519 M | -488 M | -459 M | 525 M | 470 M | 453 M | 408 M | |||
| Promotion And Advertising | 12 M | 10 M | 12 M | -10 M | -12 M | -12 M | -14 M | |||
| Rent And Landing Fees | -11 M | -11 M | -10 M | -11 M | ||||||
| Research Expense | 11 M | 11 M | 10 M | |||||||
| Salaries And Wages | -3 M | -2 M | -3 M | -15 M | -15 M | -17 M | -11 M | |||
| Selling And Marketing Expense | 5 M | 5 M | 5 M | 12 M | 10 M | 12 M | 275 M | 265 M | 234 M | 209 M |
| Selling Expense | 275 M | 265 M | 234 M | 209 M | ||||||
| Total Income Available For Interest Expense (EBIT) | 77 M | 103 M | 109 M | 171 M | 178 M | 151 M | 192 M | 135 M | 139 M | 143 M |
| Total Revenues | 855 M | 921 M | 999 M | 1,186 M | 1,135 M | 1,061 M | 1,189 M | 1,047 M | 1,006 M | 918 M |
| Total Expenses | 788 M | 828 M | 891 M | 1,016 M | 958 M | 915 M | 1,001 M | -915 M | -867 M | 777 M |
| Total Revenue | 855 M | 921 M | 999 M | 1,186 M | 1,135 M | 1,061 M | 1,189 M | 1,047 M | 1,006 M | 918 M |
| Amord | 152 M | 30 M | 32 M | 30 M | 31 M | 30 M | -2 M | -1 M | -1 M | -900000.0 |
| Avgshs | 19 M | 19 M | 19 M | 20 M | 21 M | 23 M | 24 M | 24 M | 48 M | 25 M |
| Avgshsdt | 19 M | 19 M | 19 M | 20 M | 21 M | 23 M | 25 M | 25 M | 50 M | 26 M |
| Basiceps | 2.2 | 3.31 | 3.6 | 5.78 | 5.89 | 4.44 | 5.24 | 2.57 | 2.07 | 3.72 |
| Basicepscont | 2.2 | 3.31 | 3.6 | 5.78 | 5.89 | 4.44 | ||||
| Cor | 161 M | 177 M | 194 M | 218 M | 209 M | 188 M | 201 M | -179 M | -180 M | 160 M |
| Depamor | 12 M | 12 M | 13 M | -15 M | -14 M | -12 M | -9 M | |||
| Dileps | 2.19 | 3.3 | 3.59 | 5.73 | 5.86 | 4.41 | 5.12 | 2.53 | 2.0 | 3.59 |
| Dilepscont | 2.19 | 3.3 | 3.59 | 5.73 | 5.86 | 4.41 | ||||
| Intinc | 11 M | 10 M | 4 M | 3 M | 3 M | 5 M | 4 M | 2 M | 1 M | 1 M |
| Netincdisc | 42 M | 64 M | 69 M | 117 M | 125 M | 101 M | 126 M | 63 M | 100 M | 95 M |
| Othincexp | 1 M | -7000.0 | -3 M | 2 M | 571000.0 | 335000.0 | 1 M | 3000.0 | 1 M | 174000.0 |
| Pretaxinc | 76 M | 102 M | 109 M | 171 M | 178 M | 150 M | 192 M | 135 M | 139 M | 143 M |
| Resdev | 12 M | 11 M | 12 M | 11 M | 11 M | 10 M | -10 M | -9 M | -9 M | -6 M |
| Sga | 263 M | 257 M | 262 M | 279 M | 261 M | 268 M | 275 M | 265 M | 234 M | 209 M |
| Shsout | 19 M | 19 M | 19 M | 19 M | 21 M | 22 M | 23 M | 24 M | 24 M | 24 M |
| Specincchg | 3 M | |||||||||
| Taxprov | 34 M | 39 M | 39 M | 54 M | 53 M | 50 M | 65 M | 72 M | 39 M | 48 M |